Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5270104
Max Phase: Preclinical
Molecular Formula: C76H104N10O9S
Molecular Weight: 1333.80
Associated Items:
ID: ALA5270104
Max Phase: Preclinical
Molecular Formula: C76H104N10O9S
Molecular Weight: 1333.80
Associated Items:
Canonical SMILES: CC(C)C[C@H]1CN(CC(N)=O)C(=O)CCSCc2ccc(cc2)C(=O)N[C@@H](CCCCN)CN(C(=O)CCc2ccccc2)CC(=O)N[C@@H](CC(C)C)CN(C(=O)CCC2CCCCC2)CC(=O)N[C@@H](Cc2ccccc2)CN(C(=O)Cc2ccc3ccccc3c2)CC(=O)N1
Standard InChI: InChI=1S/C76H104N10O9S/c1-54(2)40-65-46-83(49-68(78)87)74(93)37-39-96-53-59-27-33-62(34-28-59)76(95)82-64(26-16-17-38-77)45-84(72(91)35-30-56-18-8-5-9-19-56)50-69(88)80-66(41-55(3)4)47-85(73(92)36-31-57-20-10-6-11-21-57)51-70(89)81-67(43-58-22-12-7-13-23-58)48-86(52-71(90)79-65)75(94)44-60-29-32-61-24-14-15-25-63(61)42-60/h5,7-9,12-15,18-19,22-25,27-29,32-34,42,54-55,57,64-67H,6,10-11,16-17,20-21,26,30-31,35-41,43-53,77H2,1-4H3,(H2,78,87)(H,79,90)(H,80,88)(H,81,89)(H,82,95)/t64-,65-,66-,67-/m0/s1
Standard InChI Key: ZZAKNKYTTOPFOS-VZDLBADFSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1333.80 | Molecular Weight (Monoisotopic): 1332.7708 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Gu M, Yu Y, Xue M, Jiang J, Cai J.. (2023) The discovery of cyclic γ-AApeptides as the promising ligands targeting EP2., 87 [PMID:36965536] [10.1016/j.bmcl.2023.129255] |
Source(1):